Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC-Guided Personalized Therapy vs Standard Chemotherapy in Malignant Peritoneal Mesothelioma
ChiCTR2500113061Phase 3Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine, oxaliplatin and Rivoceranib in peritoneal mesothelioma (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
gemcitabineoxaliplatinRivoceranib
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on ChiCTR2500113061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113061.